GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLY) » Definitions » Net Issuance of Debt

OPHLY (Ono Pharmaceutical Co) Net Issuance of Debt : $950 Mil (TTM As of Sep. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Ono Pharmaceutical Co Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Ono Pharmaceutical Co's net issuance of debt for the three months ended in Sep. 2024 was $0 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Sep. 2024 was $950 Mil.

Ono Pharmaceutical Co Net Issuance of Debt Historical Data

The historical data trend for Ono Pharmaceutical Co's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ono Pharmaceutical Co Net Issuance of Debt Chart

Ono Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ono Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 950.21 -

Ono Pharmaceutical Co Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $950 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ono Pharmaceutical Co Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Ono Pharmaceutical Co's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ono Pharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLY) » Definitions » Net Issuance of Debt
Comparable Companies
TSE:4151 TSE:4536 TSE:4552 TSE:4882 TSE:4578 TSE:4503 LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN BMY GILD LSE:GSK TSE:4568
Traded in Other Exchanges
OPHLF:USA 4528:Japan ON4:Germany
Address
8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, JPN, 541-8564
Website
http://www.ono.co.jp
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a world-wide business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.